Zerona® laser launched in Italy

Sept. 26, 2011 - PRLog -- Low Level Laser Therapy (3LT) at an exclusive launch event at the renowned Hotel Principe di Savoia in Milan. Designed to reduce fat and contour the body without invasive surgery, the pain-free Zerona body sculpting procedure was successfully debuted in Europe at this year’s 5¬Continent¬Congress (5CC) for Lasers and Aesthetic Medicine, and is already receiving interest from a wide range of clinics and health centres looking to offer this innovative therapy.

Founded in 1996, Erchonia is a world leading provider of Low Level Laser Technology for medical applications, working to advance the applications of 3LT through independent research and product development with the backing of the scientific and medical communities. Unlike other laser body sculpting technologies, Zerona has been proven through double-blind clinical trials to emulsify adipose tissue without the potentially harmful effects of adipocyte cell death. Zerona’s unique mode of action leads to evacuation of fatty materials from unilocular adipocytes by inducing the formation of transitory pores within the cell membrane, emulating the body’s natural mechanism of fat depletion while reducing serum LDL and triglyceride levels. Following comprehensive evaluations, Zerona received USA FDA approval and European CE marking in 2010. Over 75,000 patients have since been treated in the US with more than a 90 % satisfaction rate, and the first units have now been installed in Europe.



About Erchonia Europe
Erchonia Europe, based in Oxford, is a provider of Low Level Laser Technology (3LT) for medical applications, including the potential treatment of nail fungal infections and acne, as well as complex wound management. Erchonia Europe’s Zerona® laser is a pain-free 3LT body-sculpting procedure designed to reduce fat and contour the body without invasive surgery. Zerona has been proven through double-blind clinical trials to emulsify adipose tissue and, following comprehensive evaluations, it received USA FDA approval and European CE marking in 2010. For additional information, visit www.erchoniaeurope.com

For further information, contact:
Jeremy Fry
CEO
Erchonia Europe LLP
The Innovation Centre
99 Milton Park
Abingdon
Oxon
OX14 4RY

Tel: +44 (0)1235 841590
Email: enquiries@erchoniaeurope.com
www.erchoniaeurope.com